

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/11, A61K 45/05	A1	(11) International Publication Number: WO 98/22579 (43) International Publication Date: 28 May 1998 (28.05.98)
<p>(21) International Application Number: PCT/US97/20815</p> <p>(22) International Filing Date: 14 November 1997 (14.11.97)</p> <p>(30) Priority Data: 08/755,558 22 November 1996 (22.11.96) US</p> <p>(71) Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA [US/US]; Morrill Hall, 100 Church Street, S.E., Minneapolis, MN 55455 (US).</p> <p>(72) Inventors: LOW, Walter, C.; 19845 Sweetwater Curve, Shorewood, MN 55331 (US). WALLENFRIEDMAN, Margaret, A.; 6805 Limerick Lane, Edina, MN 55439 (US). CHIANG, Lan; 4230 Underwood Lane North, Plymouth, MN 55442 (US).</p> <p>(74) Agent: BRUESS, Steven, C.; Merchant, Gould, Smith, Edell, Welter & Schmidt, P.A., 3100 Norwest Center, 90 South Seventh Street, Minneapolis, MN 55402-4131 (US).</p>		<p>(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R) ANTISENSE OLIGONUCLEOTIDE-TREATED BREAST CANCER CELLS COMPOSITION</p> <p>(57) Abstract</p> <p>A composition and method for inhibiting the growth and metastasis of breast tumors, including a tumor immunogen derived from breast tumor cells treated with an antisense oligonucleotide complementary to a gene or mRNA for the receptor for insulin-like growth factor type 1.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R) ANTISENSE OLIGONUCLEOTIDE-TREATED BREAST CANCER CELLS COMPOSITION

Field of the Invention

5 This invention relates to a vaccine and to a therapeutic method effective for inhibiting the growth of breast tumors and inhibiting local or metastatic breast tumor reoccurrence. Specifically, the invention demonstrates that peripheral administration of breast tumor immunogens derived from breast tumor cells treated with an antisense oligonucleotide complementary to the gene or mRNA for IGF-1
10 receptor effectively inhibits the growth of breast tumor cells and prevents metastasis of tumor cells, e.g., to the brain.

Background Of the Invention

 Breast cancer is the most common malignancy in females in North
15 America, becoming clinically apparent in one out of nine women. The prevalence of breast cancer is high compared to its annual incidence in other countries (estimated at greater than four times that in the UK). Thus, a therapy for this disease would provide a significant benefit to a large number of individual patients as well as a relief of health care resources.

20 Current treatment for breast cancer is directed at non-specific elimination-resection, administration of agents toxic to growing cells, or inhibition of receptor ligands required for cell growth. Examples include radiation, cytotoxic chemotherapy (e.g., doxorubicin, cyclophosphamide, methotrexate, 5-fluorouracil, mitomycin C and mitoxantrone) or hormonal manipulation to delete (e.g., ovarian
25 ablation) or antagonize (e.g., tamoxifen, aromatase inhibitors) estrogen/progesterone stimulation of tumor growth. Because of their lack of tumor specificity, these therapies are poorly tolerated and become ineffective when the disease is widely metastatic.

 These therapies have additional limitations. High doses of cytotoxic
30 agents needed for therapeutic efficacy also destroy normal dividing immunological cells and gastrointestinal cells. Thus, administration of cytotoxic agents is limited by neutropenia, thrombocytopenia and malnutrition. Radiation and surgical

therapies are limited to relatively-localized disease. All strategies are limited by the degree of deformity and/or disability that patients are willing to tolerate for only a modest increase in survival. Thus, there is need for a therapy which specifically targets a patient's malignancy and does not reduce the quality of the patient's remaining life.

Breast cancers are difficult targets because they are heterogeneous in a variety of features, including, for example, presence and absence of estrogen and progesterone receptors, and presence and absence of amplified growth factor receptors. In addition, the tumor cells may have a variety of different mutations in somatic proto-oncogenes, such as *c-erb2*, *c-myc*, *int2*, *hst1*, *bcl1*, and *PRAD1*, or tumor suppresser genes, including *RB* and *TP53*. Further, a patient may have more than one malignant cell type in the same tumor.

A population of diversified targets however, is exactly what a host's immune system is designed to screen and selectively eliminate. Vaccine-based immunotherapy has been shown to be effective in treating animal models of other types of cancers. The diversity of targets in breast cancer plus effectiveness in other types of cancer suggests that development of a vaccine-based immunotherapy might be effective for the treatment of breast cancer.

Antisense Oligonucleotides

Antisense oligonucleotides are nucleotide sequences that are complementary to specified segments of a targeted gene or mRNA. The binding of an antisense oligonucleotide to DNA or RNA within a cell can inhibit translation or transcription in the cell, which can disrupt gene expression. Typically, antisense oligonucleotides are about 14 to about 25 nucleotides in length, since it is believed that at least about 14 bases are required to specifically target a unique mammalian gene sequence. The sequence of an antisense oligonucleotide is chosen to provide specificity for a particular mammalian gene or mRNA sequence.

Antisense oligonucleotides can be synthesized with either natural or synthetic bases and with a natural phosphate or modified phosphate or sugar backbone. For example, phosphothioate, phosphonate, and other backbone

modifications can significantly alter the biological half-life, and bioavailability of antisense oligonucleotides.

Advances in molecular biology and synthetic chemistry over the past two decades have stimulated interest in developing antisense oligonucleotides as therapeutic agents. It would be beneficial to develop an antisense oligonucleotide based therapy for breast cancer to provide targeted immunotherapy.

Insulin-like growth factor and its receptor

Growth factors and their receptors are examples of molecular switches whose activation transduces a signal to the cell nucleus that enables growth, transformation and protection from cell death. Insulin-like growth factor 1 (IGF-1) and its receptor (IGF-1R) appear to be required for mitosis in many cell types. *In vitro*, most cells in culture are dependent on IGF-1 for growth, and many tumor lines secrete IGF-1 and express IGF-1R. IGF-1R is required for the entry of stimulated lymphocytes and HL-60 cells into S Phase. In the absence of proliferation, such as in senescent human fibroblasts, IGF-1 mRNA is not detectable by reverse transcriptase polymerase chain reaction. Once these senescent cells are transfected with a temperature sensitive SV40 T antigen gene, they regain the ability to express IGF-1 mRNA at permissive temperatures. IGF-1R is also associated with growth *in vivo*. Mice with homozygous null mutations for *igf-1r* gene die shortly after birth with a body weight 30% of wild type.

The expression of IGF-1R may be required for transformation *in vitro* and for tumor maintenance *in vivo*. When the gene encoding IGF-1R is disrupted in mouse embryo fibroblasts, transformation by either Ha-*ras*, SV40 tumor antigen or both, is prevented. The transformed phenotype is restored once cells are transfected with a plasmid expressing the IGF-1R RNA. Overexpression of the IGF-1R results in increased transformability of NIH 3T3 cells. Not only is oncogenesis associated with the induction of IGF genes, but preliminary data suggests that the gene product of the retinoblastoma tumor suppresser gene inhibits the expression of the IGF-1 gene.

The IGF-1 receptor (IGF-1R) is a membrane glycoprotein composed of two alpha (Mr 130,000) and two beta (Mr 98,000) subunits linked together by

disulfide bonds. The alpha subunit binds IGF-1 and IGF-2 with equal affinity. The β -subunit has an intracellular domain with tyrosine kinase activity which upon activation by either IGF-1 or IGF-2 autophosphorylates its own β -subunit and two major substrates, insulin receptor substrate 1 and Shc. Once activated, IGF-1R transmits a signal, transduced through *ras* and *raf*, to the nucleus. IGF-1 is known to stimulate the expression of approximately 30 genes expressed in 3T3 cells, encoding both cytoplasmic and nuclear proteins. Within one minute of IGF-1R ligand binding, a series of other cellular proteins as well as nuclear proteins including the 43 kD product of the *c-jun* protooncogene, are also phosphorylated *in vitro*.

10 The IGF-1R is required for the action of several growth factors. Antisense to IGF-1R blocks the EGF stimulated proliferation of 3T3 cells overexpressing EGFR. Neither PDGFR nor EGFR antisense inhibit IGF-1 stimulated growth in cells overexpressing IGF-1R. There is evidence that other protooncogenes, such as *c-myb*, induce expression of IGF-1 and IGF-1R. When *c-myb* is overexpressed in fibroblasts, the IGF-1 requirement for growth is lost because both IGF-1 and IGF-1R mRNA is induced. When *c-myb* expression is inhibited, there is a decrease in the IGF-1R mRNA. However, inhibition of IGF-1R expression has no effect on the *c-myb* mRNA levels.

 IGF-1R antisense can inhibit the growth of cells whose growth depends on expression of IGF-1R. Cells that are exposed to IGF-1R antisense and cells that are transfected with a viral vector expressing IGF-1R antisense show diminished levels of IGF-1R protein. This results in growth inhibition in IGF-1R dependent cells like rat C6 glioblastoma cells, an IGF-1R dependent tumor cell line. Diminished tumorigenicity results from transfection of C6 glioblastoma cells with a viral vector expressing IGF-1R antisense. For example, no tumors developed in rats injected with C6 glioblastoma cells bearing a viral vector expressing IGF-1R antisense. Injection with these antisense-transfected cells can also protect rats from glioblastoma tumor formation due to subsequent injection of wild type C6 glioblastoma cells. No tumors appeared in 4 weeks after the injection of the wild-type cells. Injection of the antisense-transfected C6 glioblastoma cells also caused regression of previously established wild-type C6 glioblastoma tumors. In each of

these experiments the cells that exhibited diminished tumorigenicity or that affected tumor growth were transfected with a viral vector to express IGF-1R antisense.

Work, to date, studying IGF-1R antisense in cancer cells has been performed by transfecting cells with antisense DNA integrated in a viral vector. The consequences of inserting viral DNA into human gliomas are unknown. An estimated 23 human years of retroviral mediated gene transfer has been performed in humans without known side effects, although some of the viral vectors being used for gene therapy have the long-term potential for causing cancer. Side effects have been described in 3 monkeys at the NIH, who developed malignant T cell lymphoma after bone marrow transplant and gene transfer with a helper virus contaminated retrovirus. Aside from the potential side effects and risks of viral contamination, using viral vectors to transfect each tumor line with antisense is very labor intensive.

The practical use of antisense genetic therapy would be greatly enhanced by incorporation of antisense oligonucleotides into the breast, or other, tumor cells without the use of a retroviral vector. In light of the present shortcomings in breast cancer therapy, it would be advantageous to have a therapy that specifically inhibited the growth and metastasis of breast cancer cells without the side effects of present therapies. Antisense oligonucleotides present one avenue for such therapy, but present methods for treatment with antisense oligonucleotides require viral vectors and have not proven effective in inhibiting the growth and metastasis of breast cancer cells. Hence, there is a need for an antisense-oligonucleotide based therapy for breast cancer that eliminates use of viral vectors.

Summary of the Invention

The present invention includes a therapeutic composition useful for inhibiting the growth of breast cancer cells. The composition includes a tumor cell immunogen derived from breast cancer cells that have been treated with an IGF-1 receptor antisense oligonucleotide. Preferably, the treated breast cancer cells are inactivated, e.g., not viable.

The preferred immunogen is an inactivated cancer cell treated with IGF-1 receptor antisense oligonucleotide (AON). The immunogen can include

whole cells, cell membranes, lysates or extracts of cancer cells treated with IGF-1R antisense oligonucleotide.

The antisense oligonucleotide used to produce the immunogen is complementary to the gene or mRNA of the insulin-like growth factor type I receptor (IGF-1R). Preferably, the IGF-1R antisense oligonucleotide is about 14 to about 25 nucleotides in length. More preferably, the IGF-1R antisense oligonucleotide has a sequence complementary to the nucleotide sequence of the human IGF-1R precursor signal sequence, complementary to the nucleotide sequence at or near the initiation site, or complementary to sequence the nucleotide at or near a site for ribosome complex assembly.

More preferably, the sequence of the IGF-1 receptor antisense oligonucleotide contains the following sequence:

5' TCC TCC GGA GCC AGA CTT 3' (AON1) [SEQ ID NO:1], or

5' ACT CGT CGG CCA GAG CGA GAG 3' (AON2) [SEQ ID NO:2].

Advantageously, the IGF-1 receptor antisense oligonucleotide is modified, for example, by including synthetic bases or modifying the backbone, such as by substituting phosphothioates or phosphonates.

The invention also includes a method of preparing a therapeutic composition by treating breast cancer cells with an IGF-1 receptor antisense oligonucleotide.

Another embodiment of the invention is a tumor cell immunogen derived from a breast cancer cell treated with an IGF-1 receptor antisense oligonucleotide.

A further embodiment of the invention is an IGF-1 receptor antisense oligonucleotide having the sequence:

5' ACT CGT CGG CCA GAG CGA GAG 3' (AON2) [SEQ ID NO:2].

The invention also includes using the tumor cell immunogen in a method of immunizing a breast cancer patient; in a method of inhibiting growth of breast cancer cells; in a method of inhibiting metastasis of breast cancer cells, including the inhibition of breast cancer cell metastasis behind the blood-brain-barrier; and, in a method of treating breast cancer. Each of these methods includes administering to a patient a tumor immunogen produced by treating breast cancer

cells with an IGF-1 receptor antisense oligonucleotide and thereby inducing an anti-tumor response.

Brief Description of the Figures

5 FIG. 1 is a graph showing the effects of treatment with irradiated cells pretreated with IGF-1 receptor antisense oligonucleotide AON1 on tumor volume in rats with MAT3B breast tumors.

 FIG. 2 is a graph showing the effect of treatment with irradiated cells pretreated with IGF-1 receptor antisense oligonucleotide AON1 on survival of rats
10 with MAT3B breast tumors.

 FIG. 3 is a graph showing the effect of treatment with irradiated cells pretreated with IGF-1 receptor antisense oligonucleotide AON2 on tumor volume in rats with MAT3B breast tumors.

 FIG. 4 is a graph showing the effect of treatment with irradiated cells
15 pretreated with IGF-1 receptor antisense oligonucleotide AON2 on survival of rats with MAT3B breast tumors.

 FIG. 5 is a graph showing the effect of treatment with irradiated cells pretreated with IGF-1 receptor antisense oligonucleotides AON-1 or AON-2 on survival of rats with intracerebral tumors of MAT3B breast tumor cells.

20 FIG. 6 shows the nucleotide sequence of the cDNA clone of the IGF-1 receptor [SEQ ID NO:4] and the predicted amino acid sequence as reported by Ullrich et al., *EMBO J* 5:2503-2512 (1986). The α subunit includes the amino acids numbered 31-740, the putative precursor processing sequence is at amino acids 737-740, and the β subunit amino acids 741-1367. Amino acids 1-30 are a 30 residue
25 signal sequence. Amino acids 936-959 are believed to form a transmembrane domain.

Detailed Description of the Preferred Embodiments

Antisense Oligonucleotides

30 Antisense oligonucleotides are nucleotide sequences that are complementary to specified segments of a targeted gene or mRNA. In the present

invention, an IGF-1 receptor antisense oligonucleotide is complementary to a segment of the IGF-1 receptor gene, or to IGF-1 receptor mRNA.

The antisense oligonucleotides of the invention are preferably about 14-25 nucleotides in length. Most preferably, the oligonucleotides are about 15-20 nucleotides in length. It has been estimated that an antisense oligonucleotide containing at least 14 bases is required to specifically target a unique mammalian gene sequence, so longer oligonucleotides can provide greater specificity for targeting a specific sequence. However, small oligonucleotides are advantageous because they are typically more readily taken up by cells and can exhibit improved absorbtion and like properties. Thus, the most preferred size, 15-20 nucleotides, is chosen to balance target specificity and improved uptake by cells. The preferred oligonucleotide sequence can form Watson-Crick type base pairs along the entire target sequence, but less base pairing can be tolerated when advantageous cellular uptake, pharmacokinetics, or metabolism and adequate target recognition result from the altered sequence.

The particular sequence of the nucleotides provides the molecule with the specificity for targeting genetic material, such as DNA or mRNA. The antisense oligonucleotides of the invention have sequences that are complementary to the IGF-1 receptor gene or mRNA. Preferred oligonucleotides are those that are complementary to a sequence encoding the IGF-1 receptor precursor signal peptide, to sequences at or near the initiation site (AUG codon), or those sequences at or near a site for ribosome complex assembly, a site at which a ribosome binds to a polynucleotide. A sequence is near a site on an oligo- or polynucleotide if a complementary sequence would overlap with or interfere with the function of the site.

Most preferred antisense oligonucleotides of the invention are oligonucleotides AON1 [SEQ ID NO:1] and AON2 [SEQ ID NO:2] having the nucleotide sequences shown above. The antisense oligonucleotides can be produced by known, standard methods including chemical synthesis.

The antisense oligonucleotides of the invention can be chemically modified, such as by including synthetic bases or by modifications of the phosphate or sugar backbone. Such chemical modification can increase the stability and

biological half-life of these compounds by reducing sensitivity to degradation by exonucleases, such as 3'-exonucleases, and endonucleases. Preferred are modifications that affect the phosphate backbone such as phosphorothioate-, phosphorodithioate-, methylphosphonate-, and phosphoramidite modified oligomers, as these are stable and typically resistant to degradation by nucleases. The biological half-life of a phosphorothioate antisense sequence, for example, has been determined to be approximately 48 hours. The ribose moiety of the sugar backbone can be modified as well. For example, 2'-methyl-ribonucleotides and alpha-anomer nucleotides can be incorporated into the antisense oligonucleotides. Production and properties of modified oligonucleotides is described in "*Oligonucleotides - Antisense Inhibitors of Gene Expression*", J.S. Cohen ed., CRC Press, Inc., Boca Raton, FL (1989).

The amount of antisense oligonucleotide required in the treatment of breast tumor cells is an amount effective to increase the activity of the breast tumor cells as tumor immunogen. Preferably, the antisense oligonucleotide is effective to produce an immunogen of potency such that a subject can be inoculated with an equivalent of about 2.5×10^9 treated cells per 75 kg person. In preparing the immunogen of the invention about 30×10^6 cells are incubated in a solution of about 5 μ M to about 80 μ M antisense oligonucleotide, more preferably about 10 μ M to about 40 μ M antisense oligonucleotide. The antisense oligonucleotide can be added to cells in suspension or culture, in cell culture medium or another vehicle.

Mechanisms of Antisense Action

In the present invention, treatment of breast tumor cells with an IGF-1 receptor antisense oligonucleotide modifies the tumor cells to produce a breast tumor immunogen. Such a modified breast tumor cell is a preferred tumor immunogen for use to inhibit the growth of breast cancer cells.

Although not limiting to the present invention, there are several mechanisms that can account for production of such an immunogen. For example, treatment with the antisense oligonucleotide could result in a change in phenotype of the treated cell, so the cell becomes a tumor immunogen. Alternatively, gene expression could be altered with resulting increased expression or display of an

antigen or immunogen to breast tumor on the treated cells. It is believed that binding of an antisense oligonucleotide to DNA or RNA within a cell can inhibit translation and transcription, which can disrupt gene expression.

Several theories have been advanced to explain the general action of antisense oligonucleotides in a variety of systems. Proposed mechanisms of action for antisense oligonucleotides can be classified as passive, reactive, and activating. Passive blocking of function occurs by steric hindrance whereby an mRNA molecule cannot effectively interact with ribosomes, or is unable to pass from the nucleus to the cytoplasm. Reactive processes occur where antisense oligonucleotides bind directly with a target sequence and either block its action or cause its cleavage.

For example, binding of antisense oligonucleotides to target DNA can interrupt gene transcription, or if the antisense oligonucleotide binds to mRNA, translation will be disrupted. Consequently, the synthesis of a particular protein product can be inhibited. In cell-free translation systems, the best mRNA target sites are considered the 5' end (at or near the initiation AUG codon) and at or near the sites for ribosome complex assembly. Cleavage is advantageous because it destroys the target DNA or RNA. In addition, when a target DNA or RNA is cleaved, the antisense oligonucleotide will be released intact to recycle and bind to other target sequences. The activating mechanisms of RNase H result in the digestion of the target mRNA irrespective of the point of antisense attachment.

Modification of the antisense oligonucleotide can have advantageous effects on the mechanism or action of the antisense oligonucleotide. For example, phosphodiester antisense oligonucleotides hybridize very efficiently to complementary RNA sequences and thereby block translation, but they also can recruit the enzyme RNase H which cleaves the RNA component of the RNA/DNA duplex. Methylphosphonate antisense oligonucleotides are readily taken up by cells, have low toxicity and high stability, however, they hybridize poorly and may not induce the activity of RNase. Phosphorothioate antisense oligonucleotides, in contrast, hybridize efficiently and induce RNase in a concentration-dependent fashion. Based on these theories of action, phosphorothioate antisense oligonucleotides with resistance to endonuclease activity can be advantageous in the immunogens and methods of the invention.

Treated Tumor Cells

Tumor immunogen of the present invention is preferably whole tumor or cancer cells that have been treated with an antisense oligonucleotide
5 complementary to the IGF-I receptor gene or mRNA. Immunogen, as used herein, refers to a substance that can induce an immune response, including either a humoral and/or cellular immune response. The tumor immunogen may also be derived from treated tumor cells by subjecting them to processes such as altering growth media, washing, purification, isolation, freezing, inactivation, lysis, extraction, and the like.

10 Treatment can include a single dose or multiple doses of antisense oligonucleotide. Preferably, the tumor cells are treated with two doses of antisense oligonucleotide. Typically, when treatment includes two doses of oligonucleotide, one dose of antisense is added at the beginning of the incubation and a second is added about half way through the incubation. Preferably, for treatment, the cells are
15 incubated with antisense oligonucleotide for about 23 hours, then maintained in culture for about one to two hours prior to use as a vaccine or immunogen, or before further processing. Treatment of cells is preferably under culture conditions favorable for the tumor cell type, generally at a temperature of 37°C and in a nutrient medium such as RPMI cell culture medium.

20 After treatment with antisense oligonucleotide, the treated cells are inactivated, preferably by irradiation. Treated, inactivated cells are preserved by methods, such as quick freezing at -80°C, that maintain the immunogenicity of the stored cells. This process yields tumor immunogen derived from treated breast cancer cells. The conditions of culture and incubation with the antisense
25 oligonucleotide can be chosen to provide for effective production of tumor immunogen.

The tumor immunogen is preferably prepared from a specific patient's tumor, e.g. from biopsy tissue or from explants of a removed tumor, or from cell culture of the patient's tumor cells. A patient's breast tumor cells can be
30 obtained by standard biopsy methods. Cells from excised tumor tissue can be used directly, or alternatively, cells from the excised tumor can be cultured and expanded under standard culture conditions to produce increased numbers of cells. Tumor

cells from a patient can also be used to establish a permanent tumor cell line that can then be treated to make the immunogen of the invention, the immunogen or vaccine of the invention, or used in the methods of the invention.

5 Tumor cells are preferably inactivated, e.g., by methods known in the field, the most common method being irradiation as described in the examples below. Other known inactivation methods include oxygen deprivation, use of plant and animal toxins, and chemotherapeutic agents. In an alternative embodiment, lysed tumor cells may be used as the tumor immunogen, as well as cell membranes and specific tumor cell protein immunogens; however, inactivated whole tumor cells
10 are preferred.

For administration, the tumor immunogen is suspended in an aqueous medium such as phosphate buffered saline. The amount of tumor immunogen administered is that sufficient to induce an immune response. In rat studies, administration of 5×10^6 irradiated tumor cells in 300 μ L phosphate buffered saline
15 was efficient in preventing tumor growth. Thus, the expected useful human dose of irradiated tumor cells for a subcutaneous injection is about 2.5×10^9 cells per 75 kg person. Administration of other types of tumor immunogens, e.g. cell membrane or purified tumor cell immunogens, are administered to deliver a like amount of immunogen.

20 The therapeutic composition of the invention includes tumor cell immunogen in a form suitable for administration to a patient. For example, the composition can include adjuvants, cofactors and pharmaceutically acceptable carriers, vehicles, or buffers, and the like to formulate the composition for administration to a patient. The therapeutic composition can include one or more
25 forms of the tumor cell immunogen in quantities effective to stimulate an immune response in the patient. The therapeutic composition of the invention can be formulated and administered as a vaccine. Vaccine, as used herein, refers to a therapeutic composition formulated for administration to prevent, ameliorate, or treat a disease, such as cancer.

30

Methods of Administering

For the vaccine, immunogen and methods of the invention, administration of breast tumor immunogen for inhibiting the growth of breast cancer cells and the treatment of breast tumors is to a peripheral site, preferably by
5 subcutaneous injection. Preferred peripheral sites for administration include the upper arm, thigh, and trunk areas of the body.

Timing of tumor immunogen administration is as needed to produce immune reactivity, and can be monitored by assessing change in tumor size (e.g., by MRI), immune response (e.g., by delayed type hypersensitivity skin test), and by
10 measuring interferon-gamma secretion by the patient's TH-1 cells in response to tumor immunogen. Treatment is preferably continued until immune response is detected and/or tumor ablation is achieved.

Patient Populations

15 Patients at risk of or suffering from all types of breast tumors are treated by the method of the invention. A successful peripheral administration of tumor immunogen for the treatment of breast tumor is surprising, given the distant location of the tumors. The claimed method of treating with breast cancer tumor immunogen is particularly useful in preventing tumor recurrence, for example, after
20 tumor reduction techniques, such as surgical debulking removal, irradiation, and/or chemotherapy.

Treating breast cancer tumors can also result in inhibition of growth of breast tumor cells, tumor regression, delay in or slowing of tumor growth, reduction in tumor mass, and other beneficial effects on tumor progression.
25 Inhibiting growth of breast tumor cells includes slowing division or killing the cells. Inhibited cell growth leads to slower tumor growth, which depends on growth of individual cells. Treating or preventing metastasis includes stopping, slowing, or delaying the spread of the breast cancer tumor cells to other tissues or organs in the patient. Preventing breast cancer in a patient refers to treatment of patients at risk of
30 breast cancer to delay or prevent the onset of breast cancer. Prevention can be measured as a reduction of incidence of breast cancer in a population at risk of breast cancer. Alternatively, preventing cancer in breast cancer survivors includes

inhibiting recurrence or regrowth of breast cancer. Administration of the therapeutic composition of the invention effectively inhibits regrowth of tumor, e.g. from residual tumor cells.

5

Examples

The invention will be further described by reference to the following detailed examples, which are exemplary in nature and not intended to limit the scope of the invention.

10

Example 1

Vaccination with Breast Tumor Cells Treated with IGF-1 Receptor (AON1) Antisense Oligonucleotide

Two IGF-1 receptor antisense oligonucleotides have been used to produce tumor cell immunogens for the inhibition of breast cancer growth. The first sequence used was a known antisense sequence, AON1 [SEQ ID NO:1], complementary to the nucleotide sequence of codons -29 to -24 (nucleotides -87 to -70) of the human IGF-1R precursor signal sequence. The sequence of AON1 is:

5' TCC TCC GGA GCC AGA CTT 3'

The second antisense oligonucleotide tested is AON2, [SEQ ID NO:2] described more fully below in Example 2, and having the following sequence:

5' ACT CGT CGG CCA GAG CGA GAG 3'

Vaccine Production

25

To provide tumor immunogens for immune stimulation, MAT3B cells were grown at 37°C until reaching 80 - 90 % confluence in 175 mm³ flasks of DMEM media supplemented with glycine, penicillin, streptomycin and 10% fetal calf serum. These cells were then collected, centrifuged at 1000 g x 5 minutes, washed twice in ice cold PBS, centrifuged and resuspended in each of three 175 mm³ flasks in 10 mls of serum free DMEM media supplemented with 12.5 μM IGF-1 (Upstate Biotechnology), 0.10% BSA and 10 μM FeSO₄.

30

These three flasks were used to make cells for an antisense oligonucleotide treatment, a treatment with nonsense oligonucleotide, and a vehicle control treatment. Antisense treated cells were incubated with 12 μ M IGF-1R AON (NBI, Plymouth, MN) in the first flask. Nonsense treated cells were incubated with 12 μ M IGF-1R NON in the second flask. For the vehicle control treatment, an volume of oligonucleotide buffer (PBS) equivalent to the volume used in the other flasks was added to a third flask. Cells under treatment were incubated for 24 hours and redosed with 6 μ M IGF-1R AON, 6 μ M IGF-1R NON, or oligonucleotide buffer (PBS) during the last hour of incubation prior to harvest.

The Mat3B cells were then harvested, counted with a hemocytometer, resuspended in PBS at a concentration of 10^6 per 300 μ l PBS, and irradiated with 6000 rads 137 Cs. Irradiated cells were then quick frozen in liquid nitrogen and stored at -70 °C until use (storage time varied between 0 and 48 hours).

Animal Vaccination

Female Fischer 344 rats, 150-160 gm and syngeneic for Mat3B cells, were obtained from Harlan (Indianapolis, IN) and cared for according to the University of Minnesota guidelines. Animals were either unvaccinated controls or vaccinated with Mat3B cells treated with IGF-1R AON, IGF-1R NON, or oligonucleotide buffer (PBS) as described under vaccine production. One of two vaccination protocols were used. For AON1 treated breast tumor cells, animals were vaccinated with subcutaneous hind limb injections of treated cells at 2 months and 1 month prior to tumor challenge. For AON2 or nonsense oligonucleotide treated breast tumor cells, animals were vaccinated with subcutaneous hind limb injections of treated cells or at 6 weeks, 4 weeks and 2 weeks prior to tumor challenge. Animals were vaccinated with 5×10^6 cells in 300 μ l of PBS.

Peripheral Tumor Inoculation and Evaluation

To establish a model in which tumor growth or regression could be easily quantitated on a daily basis peripheral breast cancers were then established in the opposite hind flank of the vaccinated, or unvaccinated syngeneic rodents described above. Peripheral tumors were established by injecting 10^6 unmodified

log phase Mat3B cells that had been harvested, washed and resuspended in 300 μ l PBS.

Tumor lengths and widths were then measured daily by an observer who was blinded to the vaccination group. Tumor volumes were approximated using the equation $[(\text{width})^2 \times \text{length}] / 2$, and averages \pm SEM were calculated daily for each group. Daily average tumor volumes from each group were compared over the course of the experiment using ANOVA and *post hoc* TUKEY with the SAS statistical analysis program. Groups averages were not compared after one or more animals in the group died or after all animals in the vaccination group recovered from their tumors.

Those rats which were resistant to or recovered from peripheral breast cancer were then monitored without further treatment for 2 months (AON2 or NON vaccination) to 7 months (AON1 vaccination). The tumor free rats were then rechallenged with peripheral breast cancer inoculations as above.

Results

Figure 1 shows the effect of vaccination with AON1-treated tumor cells on breast tumor volume. Both unvaccinated naive animals and animals tested with phosphate buffered saline (PBS) treated cells exhibited rapid tumor growth. In contrast, animals immunized with AON1-treated tumor cells exhibited a significant delay in tumor growth. In this latter group two animals displayed a regression of tumor volume and a third animal never developed a palpable tumor.

The survival of animals vaccinated with irradiated AON1 treated MAT3B tumor cells is shown in Figure 2. Naive control animals all died within 25 days of breast tumor implantation. Animals vaccinated with NaCl treated cells all died within 38 days. In contrast, 40% of animals with IGF-1 receptor antisense (AON1) vaccinations survived beyond 250 days post tumor implantation and continue to survive.

These studies demonstrate IGF-1 Receptor antisense oligonucleotide (AON1) when incubated with breast tumor cells produces a vaccine that prevents breast tumor cell growth in vaccinated animals.

Example 2
Vaccination with Breast Tumor Cells Treated with
IGF-1 Receptor (AON2) Antisense Oligonucleotide

5

A second antisense sequence IGF-1R AON2 was designed using a selected region of the IGF-1R gene sequence having the following sequence:

5' ACT CGT CGG CCA GAG CGA GAG 3' [SEQ ID NO:2]

A nonsense sequence used as a control having the following sequence:

10 5' TGG CAC CGT ACC AGG AGG CAG 3' [SEQ ID NO:3]

The IGF-1R AON2 sequence is complementary to a region of the IGF-1R gene that is homologous between humans, mice, and rats:

15 ...GCG**CTCTCGCTCTGGCCGACGAGT**GGAGAAATCTGC...Human
 ...GCG**CTCTCGCTCTGGCCGACGAGT**GGAGAAATTTGT...Mouse
 ...GCG**CTCTCGCTCTGGCCGACGAGT**GGAGAAATTTGT...Rat

Breast tumor cell vaccines were prepared as described in Example 1 by incubating MAT3B cells with the IGF-1 receptor antisense oligonucleotide AON2. Control vaccines were prepared by incubating MAT3B cells with the
 20 nonsense oligonucleotide (NON) and with PBS treated cells were irradiated, as described for Example 1. Syngeneic animals were immunized with the treated irradiated cells at 6, 4, and 2 weeks prior to breast tumor cell implantation, as described in Example 1. Peripheral tumors were established and evaluated as
 25 described in Example 1.

Results

The effects of this vaccine, AON2-treated tumor cells, on breast tumor growth is shown in Figure 3. Unvaccinated control animals exhibited rapid
 30 breast tumor growth as did animals vaccinated with PBS-incubated cells. Animals vaccinated with tumor cells treated with the nonsense oligonucleotide, IGF-1R NON, displayed a slightly slower growth rate of the tumor. The slowest tumor growth rate was exhibited by animals vaccinated with tumor cells treated with the

novel antisense oligonucleotide, AON2. One animal in this latter group had no palpable tumor, and one other animal exhibited a regression of its tumor.

The survival of animals vaccinated with AON2-treated cells is shown in Figure 4. Untreated control animals died within 19 days after breast tumor
5 implantation. Animals vaccinated with PBS-treated cells or cells treated with nonsense oligonucleotide all succumbed to their cancer by day 28. In contrast, 33% of the animals vaccinated with AON2-treated cells have survived beyond 125 days and continue to survive.

These studies demonstrate IGF-1 Receptor antisense oligonucleotide
10 (AON2) incubated with breast tumor cells produces a vaccine that inhibits breast tumor cell growth in immunized animals.

Example 3

The Effect the AON1 Vaccine on Breast Tumor Metastasis to the Brain

15 The therapeutic effects of animal vaccination with IGF-1 receptor antisense oligonucleotide treated cells were also examined in a model of breast tumor metastasis to the brain. Fischer 344 rats were vaccinated with either IGF-1R AON1- or AON2-treated irradiated MAT3B cells prepared and vaccinated as described above for Example 1.

20

Central Tumor Inoculation and Evaluation

In the model for breast cancer metastasis, 10^6 unmodified, log phase Mat3B cells were suspended in 10 μ l PBS and injected into the striatum of vaccinated or unvaccinated syngeneic rats. To assess the length of protection
25 provided by the vaccine, these animals were vaccinated 3 months (group 2) to 8 months (group 1) prior to intracerebral challenge.

Injections were made at the rate of 1 μ l per minute with a 5 minute pause prior to removal of the Hamilton syringe. Animals were monitored for survival. In long term survivors, the presence or absence of tumors was assessed
30 with MRI of animals anesthetized with ketamine/xylozine.

Results

All control animals (n = 10) died by day 8 after the intracerebral injections because of tumor growth within the brain (see Table 1 and FIG. 5). In contrast, 75% of the rats previously immunized with either IGF-1R AON1 or AON2-treated tumor cells survived 90 days beyond the intracerebral injection and continue to survive (FIG. 5). There was no significant difference between the animals treated with AON-1 or AON-2, and the data for these two treatments were pooled in the results reported in Table 1 and FIG. 5.

Table 1. Survival of rats with intracerebral tumors of breast carcinoma cells

Non-immunized control rats	(0/10)	0%
IGF-1R AON immunized rats	(3/4)	75%

MRI of immunized and non-immunized rats demonstrated the prevention of metastatic MAT3B breast tumor growth in the brain and the regression of tumors in vaccinated animals.

15

The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.

20

All publications and patent applications in this specification are indicative of the level of ordinary skill in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated by reference.

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: Regents of the University of Minnesota
- (ii) TITLE OF THE INVENTION: INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR
(IGF-1R) ANTISENSE OLIGONUCLEOTIDE CELLS COMPOSITION
- (iii) NUMBER OF SEQUENCES: 4
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Merchant, Gould, Smith, Edell, Welter & Schmidt
 - (B) STREET: 3100 Norwest Center, 90 S. 7th Street
 - (C) CITY: Minneapolis
 - (D) STATE: MN
 - (E) COUNTRY: U.S.A.
 - (F) ZIP: 55402
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Diskette
 - (B) COMPUTER: IBM Compatible
 - (C) OPERATING SYSTEM: DOS
 - (D) SOFTWARE: FastSEQ Version 1.5
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: Unknown
 - (B) FILING DATE: 14-NOV-1997
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/755,558
 - (B) FILING DATE: 22-NOV-1996
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Kettleberger, Denise M
 - (B) REGISTRATION NUMBER: 33,924
 - (C) REFERENCE/DOCKET NUMBER: 600.337W001
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 612/332-5300
 - (B) TELEFAX: 612/332-9081
 - (C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TCCTCCGGAG CCAGACTT

18

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

ACTCGTCGGC CAGAGCGAGA G

21

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TGGCACCGTA CCAGGAGGCA G

21

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4989 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA
 (iii) HYPOTHETICAL: NO
 (iv) ANTISENSE: NO
 (v) FRAGMENT TYPE:
 (vi) ORIGINAL SOURCE:
 (ix) FEATURE:

(A) NAME/KEY: Coding Sequence
 (B) LOCATION: 46...4149
 (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

TTTTTTTTTT TTTTGAGAAA GGGAATTTCa TCCCAAATAA AAGGA ATG AAG TCT GGC      57
                                     Met Lys Ser Gly
                                     1

TCC GGA GGA GGG TCC CCG ACC TCG CTG TGG GGG CTC CTG TTT CTC TCC      105
Ser Gly Gly Gly Ser Pro Thr Ser Leu Trp Gly Leu Leu Phe Leu Ser
  5                      10                      15                      20

GCC GCG CTC TCG CTC TGG CCG ACG AGT GGA GAA ATC TGC GGG CCA GGC      153
Ala Ala Leu Ser Leu Trp Pro Thr Ser Gly Glu Ile Cys Gly Pro Gly
                25                      30                      35

ATC GAC ATC CGC AAC GAC TAT CAG CAG CTG AAG CGC CTG GAG AAC TGC      201
Ile Asp Ile Arg Asn Asp Tyr Gln Gln Leu Lys Arg Leu Glu Asn Cys
                40                      45                      50

ACG GTG ATC GAG GGC TAC CTC CAC ATC CTG CTC ATC TCC AAG GCC GAG      249
Thr Val Ile Glu Gly Tyr Leu His Ile Leu Leu Ile Ser Lys Ala Glu
                55                      60                      65

GAC TAC CGC AGC TAC CGC TTC CCC AAG CTC ACG GTC ATT ACC GAG TAC      297
Asp Tyr Arg Ser Tyr Arg Phe Pro Lys Leu Thr Val Ile Thr Glu Tyr
  70                      75                      80

TTG CTG CTG TTC CGA GTG GCT GGC CTC GAG AGC CTC GGA GAC CTC TTC      345
Leu Leu Leu Phe Arg Val Ala Gly Leu Glu Ser Leu Gly Asp Leu Phe
  85                      90                      95                      100

CCC AAC CTC ACG GTC ATC CGC GGC TGG AAA CTC TTC TAC AAC TAC GCC      393
Pro Asn Leu Thr Val Ile Arg Gly Trp Lys Leu Phe Tyr Asn Tyr Ala
                105                      110                      115

CTG GTC ATC TTC GAG ATG ACC AAT CTC AAG GAT ATT GGG CTT TAC AAC      441
Leu Val Ile Phe Glu Met Thr Asn Leu Lys Asp Ile Gly Leu Tyr Asn
                120                      125                      130

CTG AGG AAC ATT ACT CGG GGG GCC ATC AGG ATT GAG AAA AAT GCT GAC      489
Leu Arg Asn Ile Thr Arg Gly Ala Ile Arg Ile Glu Lys Asn Ala Asp
                135                      140                      145

CTC TGT TAC CTC TCC ACT GTG GAC TGG TCC CTG ATC CTG GAT GCG GTG      537
Leu Cys Tyr Leu Ser Thr Val Asp Trp Ser Leu Ile Leu Asp Ala Val
                150                      155                      160

TCC AAT AAC TAC ATT GTG GGG AAT AAG CCC CCA AAG GAA TGT GGG GAC      585
Ser Asn Asn Tyr Ile Val Gly Asn Lys Pro Pro Lys Glu Cys Gly Asp
  165                      170                      175                      180

CTG TGT CCA GGG ACC ATG GAG GAG AAG CCG ATG TGT GAG AAG ACC ACC      633
Leu Cys Pro Gly Thr Met Glu Glu Lys Pro Met Cys Glu Lys Thr Thr
                185                      190                      195

```


ATC	AAC	AAT	GAG	TAC	AAC	TAC	CGC	TGC	TGG	ACC	ACA	AAC	CGC	TGC	CAG	681
Ile	Asn	Asn	Glu	Tyr	Asn	Tyr	Arg	Cys	Trp	Thr	Thr	Asn	Arg	Cys	Gln	
			200					205					210			
AAA	ATG	TGC	CCA	AGC	ACG	TGT	GGG	AAG	CGG	GCG	TGC	ACC	GAG	AAC	AAT	729
Lys	Met	Cys	Pro	Ser	Thr	Cys	Gly	Lys	Arg	Ala	Cys	Thr	Glu	Asn	Asn	
		215					220					225				
GAG	TGC	TGC	CAC	CCC	GAG	TGC	CTG	GGC	AGC	TGC	AGC	GCG	CCT	GAC	AAC	777
Glu	Cys	Cys	His	Pro	Glu	Cys	Leu	Gly	Ser	Cys	Ser	Ala	Pro	Asp	Asn	
	230					235					240					
GAC	ACG	GCC	TGT	GTA	GCT	TGC	CGC	CAC	TAC	TAC	TAT	GCC	GGT	GTC	TGT	825
Asp	Thr	Ala	Cys	Val	Ala	Cys	Arg	His	Tyr	Tyr	Tyr	Ala	Gly	Val	Cys	
	245				250				255						260	
GTG	CCT	GCC	TGC	CCG	CCC	AAC	ACC	TAC	AGG	TTT	GAG	GGC	TGG	CGC	TGT	873
Val	Pro	Ala	Cys	Pro	Pro	Asn	Thr	Tyr	Arg	Phe	Glu	Gly	Trp	Arg	Cys	
				265					270					275		
GTG	GAC	CGT	GAC	TTC	TGC	GCC	AAC	ATC	CTC	AGC	GCC	GAG	AGC	AGC	GAC	921
Val	Asp	Arg	Asp	Phe	Cys	Ala	Asn	Ile	Leu	Ser	Ala	Glu	Ser	Ser	Asp	
			280					285					290			
TCC	GAG	GGG	TTT	GTG	ATC	CAC	GAC	GGC	GAG	TGC	ATG	CAG	GAG	TGC	CCC	969
Ser	Glu	Gly	Phe	Val	Ile	His	Asp	Gly	Glu	Cys	Met	Gln	Glu	Cys	Pro	
		295					300					305				
TCG	GGC	TTC	ATC	CGC	AAC	GGC	AGC	CAG	AGC	ATG	TAC	TGC	ATC	CCT	TGT	1017
Ser	Gly	Phe	Ile	Arg	Asn	Gly	Ser	Gln	Ser	Met	Tyr	Cys	Ile	Pro	Cys	
	310					315					320					
GAA	GGT	CCT	TGC	CCG	AAG	GTC	TGT	GAG	GAA	GAA	AAG	AAA	ACA	AAG	ACC	1065
Glu	Gly	Pro	Cys	Pro	Lys	Val	Cys	Glu	Glu	Glu	Lys	Lys	Thr	Lys	Thr	
	325				330					335					340	
ATT	GAT	TCT	GTT	ACT	TCT	GCT	CAG	ATG	CTC	CAA	GGA	TGC	ACC	ATC	TTC	1113
Ile	Asp	Ser	Val	Thr	Ser	Ala	Gln	Met	Leu	Gln	Gly	Cys	Thr	Ile	Phe	
				345					350					355		
AAG	GGC	AAT	TTG	CTC	ATT	AAC	ATC	CGA	CGG	GGG	AAT	AAC	ATT	GCT	TCA	1161
Lys	Gly	Asn	Leu	Leu	Ile	Asn	Ile	Arg	Arg	Gly	Asn	Asn	Ile	Ala	Ser	
			360					365					370			
GAG	CTG	GAG	AAC	TTC	ATG	GGG	CTC	ATC	GAG	GTG	GTG	ACG	GGC	TAC	GTG	1209
Glu	Leu	Glu	Asn	Phe	Met	Gly	Leu	Ile	Glu	Val	Val	Thr	Gly	Tyr	Val	
		375					380					385				

AAG	ATC	CGC	CAT	TCT	CAT	GCC	TTG	GTC	TCC	TTG	TCC	TTC	CTA	AAA	AAC	1257
Lys	Ile	Arg	His	Ser	His	Ala	Leu	Val	Ser	Leu	Ser	Phe	Leu	Lys	Asn	
	390					395					400					
CTT	CGC	CTC	ATC	CTA	GGA	GAG	GAG	CAG	CTA	GAA	GGG	AAT	TAC	TCC	TTC	1305
Leu	Arg	Leu	Ile	Leu	Gly	Glu	Glu	Gln	Leu	Glu	Gly	Asn	Tyr	Ser	Phe	
405					410					415					420	
TAC	GTC	CTC	GAC	AAC	CAG	AAC	TTG	CAG	CAA	CTG	TGG	GAC	TGG	GAC	CAC	1353
Tyr	Val	Leu	Asp	Asn	Gln	Asn	Leu	Gln	Gln	Leu	Trp	Asp	Trp	Asp	His	
			425						430					435		
CGC	AAC	CTG	ACC	ATC	AAA	GCA	GGG	AAA	ATG	TAC	TTT	GCT	TTC	AAT	CCC	1401
Arg	Asn	Leu	Thr	Ile	Lys	Ala	Gly	Lys	Met	Tyr	Phe	Ala	Phe	Asn	Pro	
			440					445					450			
AAA	TTA	TGT	GTT	TCC	GAA	ATT	TAC	CGC	ATG	GAG	GAA	GTG	ACG	GGG	ACT	1449
Lys	Leu	Cys	Val	Ser	Glu	Ile	Tyr	Arg	Met	Glu	Glu	Val	Thr	Gly	Thr	
	455						460					465				
AAA	GGG	CGC	CAA	AGC	AAA	GGG	GAC	ATA	AAC	ACC	AGG	AAC	AAC	GGG	GAG	1497
Lys	Gly	Arg	Gln	Ser	Lys	Gly	Asp	Ile	Asn	Thr	Arg	Asn	Asn	Gly	Glu	
	470					475					480					
AGA	GCC	TCC	TGT	GAA	AGT	GAC	GTC	CTG	CAT	TTC	ACC	TCC	ACC	ACC	ACG	1545
Arg	Ala	Ser	Cys	Glu	Ser	Asp	Val	Leu	His	Phe	Thr	Ser	Thr	Thr	Thr	
485					490					495					500	
TCG	AAG	AAT	CGC	ATC	ATC	ATA	ACC	TGG	CAC	CGG	TAC	CGG	CCC	CCT	GAC	1593
Ser	Lys	Asn	Arg	Ile	Ile	Ile	Thr	Trp	His	Arg	Tyr	Arg	Pro	Pro	Asp	
				505					510					515		
TAC	AGG	GAT	CTC	ATC	AGC	TTC	ACC	GTT	TAC	TAC	AAG	GAA	GCA	CCC	TTT	1641
Tyr	Arg	Asp	Leu	Ile	Ser	Phe	Thr	Val	Tyr	Tyr	Lys	Glu	Ala	Pro	Phe	
			520					525					530			
AAG	AAT	GTC	ACA	GAG	TAT	GAT	GGG	CAG	GAT	GCC	TGC	GGC	TCC	AAC	AGC	1689
Lys	Asn	Val	Thr	Glu	Tyr	Asp	Gly	Gln	Asp	Ala	Cys	Gly	Ser	Asn	Ser	
		535					540					545				
TGG	AAC	ATG	GTG	GAC	GTG	GAC	CTC	CCG	CCC	AAC	AAG	GAC	GTG	GAG	CCC	1737
Trp	Asn	Met	Val	Asp	Val	Asp	Leu	Pro	Pro	Asn	Lys	Asp	Val	Glu	Pro	
	550					555					560					
GGC	ATC	TTA	CTA	CAT	GGG	CTG	AAG	CCC	TGG	ACT	CAG	TAC	GCC	GTT	TAC	1785
Gly	Ile	Leu	Leu	His	Gly	Leu	Lys	Pro	Trp	Thr	Gln	Tyr	Ala	Val	Tyr	
565					570					575					580	
GTC	AAG	GCT	GTG	ACC	CTC	ACC	ATG	GTG	GAG	AAC	GAC	CAT	ATC	CGT	GGG	1833
Val	Lys	Ala	Val	Thr	Leu	Thr	Met	Val	Glu	Asn	Asp	His	Ile	Arg	Gly	
				585					590					595		
GCC	AAG	AGT	GAG	ATC	TTG	TAC	ATT	CGC	ACC	AAT	GCT	TCA	GTT	CCT	TCC	1881
Ala	Lys	Ser	Glu	Ile	Leu	Tyr	Ile	Arg	Thr	Asn	Ala	Ser	Val	Pro	Ser	
			600					605						610		

ATT CCC TTG GAC GTT CTT TCA GCA TCG AAC TCC TCT TCT CAG TTA ATC Ile Pro Leu Asp Val Leu Ser Ala Ser Asn Ser Ser Ser Gln Leu Ile 615 620 625	1929
GTG AAG TGG AAC CCT CCC TCT CTG CCC AAC GGC AAC CTG AGT TAC TAC Val Lys Trp Asn Pro Pro Ser Leu Pro Asn Gly Asn Leu Ser Tyr Tyr 630 635 640	1977
ATT GTG CGC TGG CAG CGG CAG CCT CAG GAC GGC TAC CTT TAC CGG CAC Ile Val Arg Trp Gln Arg Gln Pro Gln Asp Gly Tyr Leu Tyr Arg His 645 650 655 660	2025
AAT TAC TGC TCC AAA GAC AAA ATC CCC ATC AGG AAG TAT GCC GAC GGC Asn Tyr Cys Ser Lys Asp Lys Ile Pro Ile Arg Lys Tyr Ala Asp Gly 665 670 675	2073
ACC ATC GAC ATT GAG GAG GTC ACA GAG AAC CCC AAG ACT GAG GTG TGT Thr Ile Asp Ile Glu Glu Val Thr Glu Asn Pro Lys Thr Glu Val Cys 680 685 690	2121
GGT GGG GAG AAA GGG CCT TGC TGC GCC TGC CCC AAA ACT GAA GCC GAG Gly Gly Glu Lys Gly Pro Cys Cys Ala Cys Pro Lys Thr Glu Ala Glu 695 700 705	2169
AAG CAG GCC GAG AAG GAG GAG GCT GAA TAC CGC AAA GTC TTT GAG AAT Lys Gln Ala Glu Lys Glu Glu Ala Glu Tyr Arg Lys Val Phe Glu Asn 710 715 720	2217
TTC CTG CAC AAC TCC ATC TTC GTG CCC AGA CCT GAA AGG AAG CGG AGA Phe Leu His Asn Ser Ile Phe Val Pro Arg Pro Glu Arg Lys Arg Arg 725 730 735 740	2265
GAT GTC ATG CAA GTG GCC AAC ACC ACC ATG TCC AGC CGA AGC AGG AAC Asp Val Met Gln Val Ala Asn Thr Thr Met Ser Ser Arg Ser Arg Asn 745 750 755	2313
ACC ACG GCC GCA GAC ACC TAC AAC ATC ACC GAC CCG GAA GAG CTG GAG Thr Thr Ala Ala Asp Thr Tyr Asn Ile Thr Asp Pro Glu Glu Leu Glu 760 765 770	2361
ACA GAG TAC CCT TTC TTT GAG AGC AGA GTG GAT AAC ACG GAG AGA ACT Thr Glu Tyr Pro Phe Phe Glu Ser Arg Val Asp Asn Thr Glu Arg Thr 775 780 785	2409
GTC ATT TCT AAC CTT CGG CCT TTC ACA TTG TAC CGC ATC GAT ATC CAC Val Ile Ser Asn Leu Arg Pro Phe Thr Leu Tyr Arg Ile Asp Ile His 790 795 800	2457
AGC TGC AAC CAC GAG GCT GAG AAG CTG GGC TGC AGC GCC TCC AAC TTC Ser Cys Asn His Glu Ala Glu Lys Leu Gly Cys Ser Ala Ser Asn Phe 805 810 815 820	2505
GTC TTT GCA AGG ACT ATG CCC GCA GAA GGA GCA GAT GAC ATT CCT GGG Val Phe Ala Arg Thr Met Pro Ala Glu Gly Ala Asp Asp Ile Pro Gly 825 830 835	2553

CCA GTG ACC TGG GAG CCA AGG CCT GAA AAC TCC ATC TTT TTA AAG TGG	2601
Pro Val Thr Trp Glu Pro Arg Pro Glu Asn Ser Ile Phe Leu Lys Trp	
840 845 850	
CCG GAA CCT GAG AAT CCC AAT GGA TTG ATT CTA ATG TAT GAA ATA AAA	2649
Pro Glu Pro Glu Asn Pro Asn Gly Leu Ile Leu Met Tyr Glu Ile Lys	
855 860 865	
TAC GGA TCA CAA GTT GAG GAT CAG CGA GAA TGT GTG TCC AGA CAG GAA	2697
Tyr Gly Ser Gln Val Glu Asp Gln Arg Glu Cys Val Ser Arg Gln Glu	
870 875 880	
TAC AGG AAG TAT GGA GGG GCC AAG CTA AAC CGG CTA AAC CCG GGG AAC	2745
Tyr Arg Lys Tyr Gly Gly Ala Lys Leu Asn Arg Leu Asn Pro Gly Asn	
885 890 895 900	
TAC ACA GCC CGG ATT CAG GCC ACA TCT CTC TCT GGG AAT GGG TCG TGG	2793
Tyr Thr Ala Arg Ile Gln Ala Thr Ser Leu Ser Gly Asn Gly Ser Trp	
905 910 915	
ACA GAT CCT GTG TTC TTC TAT GTC CAG GCC AAA ACA GGA TAT GAA AAC	2841
Thr Asp Pro Val Phe Phe Tyr Val Gln Ala Lys Thr Gly Tyr Glu Asn	
920 925 930	
TTC ATC CAT CTG ATC ATC GCT CTG CCC GTC GCT GTC CTG TTG ATC GTG	2889
Phe Ile His Leu Ile Ile Ala Leu Pro Val Ala Val Leu Leu Ile Val	
935 940 945	
GGA GGG TTG GTG ATT ATG CTG TAC GTC TTC CAT AGA AAG AGA AAT AAC	2937
Gly Gly Leu Val Ile Met Leu Tyr Val Phe His Arg Lys Arg Asn Asn	
950 955 960	
AGC AGG CTG GGG AAT GGA GTG CTG TAT GCC TCT GTG AAC CCG GAG TAC	2985
Ser Arg Leu Gly Asn Gly Val Leu Tyr Ala Ser Val Asn Pro Glu Tyr	
965 970 975 980	
TTC AGC GCT GCT GAT GTG TAC GTT CCT GAT GAG TGG GAG GTG GCT CGG	3033
Phe Ser Ala Ala Asp Val Tyr Val Pro Asp Glu Trp Glu Val Ala Arg	
985 990 995	
GAG AAG ATC ACC ATG AGC CGG GAA CTT GGG CAG GGG TCG TTT GGG ATG	3081
Glu Lys Ile Thr Met Ser Arg Glu Leu Gly Gln Gly Ser Phe Gly Met	
1000 1005 1010	
GTC TAT GAA GGA GTT GCC AAG GGT GTG GTG AAA GAT GAA CCT GAA ACC	3129
Val Tyr Glu Gly Val Ala Lys Gly Val Val Lys Asp Glu Pro Glu Thr	
1015 1020 1025	
AGA GTG GCC ATT AAA ACA GTG AAC GAG GCC GCA AGC ATG CGT GAG AGG	3177
Arg Val Ala Ile Lys Thr Val Asn Glu Ala Ala Ser Met Arg Glu Arg	
1030 1035 1040	
ATT GAG TTT CTC AAC GAA GCT TCT GTG ATG AAG GAG TTC AAT TGT CAC	3225
Ile Glu Phe Leu Asn Glu Ala Ser Val Met Lys Glu Phe Asn Cys His	
1045 1050 1055 1060	

CAT GTG GTG CGA TTG CTG GGT GTG GTG TCC CAA GGC CAG CCA ACA CTG His Val Val Arg Leu Leu Gly Val Val Ser Gln Gly Gln Pro Thr Leu 1065 1070 1075	3273
GTC ATC ATG GAA CTG ATG ACA CGG GGC GAT CTC AAA AGT TAT CTC CGG Val Ile Met Glu Leu Met Thr Arg Gly Asp Leu Lys Ser Tyr Leu Arg 1080 1085 1090	3321
TCT CTG AGG CCA GAA ATG GAG AAT AAT CCA GTC CTA GCA CCT CCA AGC Ser Leu Arg Pro Glu Met Glu Asn Asn Pro Val Leu Ala Pro Pro Ser 1095 1100 1105	3369
CTG AGC AAG ATG ATT CAG ATG GCC GGA GAG ATT GCA GAC GGC ATG GCA Leu Ser Lys Met Ile Gln Met Ala Gly Glu Ile Ala Asp Gly Met Ala 1110 1115 1120	3417
TAC CTC AAC GCC AAT AAG TTC GTC CAC AGA GAC CTT GCT GCC CGG AAT Tyr Leu Asn Ala Asn Lys Phe Val His Arg Asp Leu Ala Ala Arg Asn 1125 1130 1135 1140	3465
TGC ATG GTA GCC GAA GAT TTC ACA GTC AAA ATC GGA GAT TTT GGT ATG Cys Met Val Ala Glu Asp Phe Thr Val Lys Ile Gly Asp Phe Gly Met 1145 1150 1155	3513
ACG CGA GAT ATC TAT GAG ACA GAC TAT TAC CGG AAA GGA GGC AAA GGG Thr Arg Asp Ile Tyr Glu Thr Asp Tyr Tyr Arg Lys Gly Gly Lys Gly 1160 1165 1170	3561
CTG CTG CCC GTG CGC TGG ATG TCT CCT GAG TCC CTC AAG GAT GGA GTC Leu Leu Pro Val Arg Trp Met Ser Pro Glu Ser Leu Lys Asp Gly Val 1175 1180 1185	3609
TTC ACC ACT TAC TCG GAC GTC TGG TCC TTC GGG GTC GTC CTC TGG GAG Phe Thr Thr Tyr Ser Asp Val Trp Ser Phe Gly Val Val Leu Trp Glu 1190 1195 1200	3657
ATC GCC ACA CTG GCC GAG CAG CCC TAC CAG GGC TTG TCC AAC GAG CAA Ile Ala Thr Leu Ala Glu Gln Pro Tyr Gln Gly Leu Ser Asn Glu Gln 1205 1210 1215 1220	3705
GTC CTT CGC TTC GTC ATG GAG GGC GGC CTT CTG GAC AAG CCA GAC AAC Val Leu Arg Phe Val Met Glu Gly Gly Leu Leu Asp Lys Pro Asp Asn 1225 1230 1235	3753
TGT CCT GAC ATG CTG TTT GAA CTG ATG CGC ATG TGC TGG CAG TAT AAC Cys Pro Asp Met Leu Phe Glu Leu Met Arg Met Cys Trp Gln Tyr Asn 1240 1245 1250	3801
CCC AAG ATG AGG CCT TCC TTC CTG GAG ATC ATC AGC AGC ATC AAA GAG Pro Lys Met Arg Pro Ser Phe Leu Glu Ile Ile Ser Ser Ile Lys Glu 1255 1260 1265	3849
GAG ATG GAG CCT GGC TTC CGG GAG GTC TCC TTC TAC TAC AGC GAG GAG Glu Met Glu Pro Gly Phe Arg Glu Val Ser Phe Tyr Tyr Ser Glu Glu 1270 1275 1280	3897

AAC AAG CTG CCC GAG CCG GAG GAG CTG GAC CTG GAG CCA GAG AAC ATG	3945
Asn Lys Leu Pro Glu Pro Glu Glu Leu Asp Leu Glu Pro Glu Asn Met	
1285 1290 1295 1300	
GAG AGC GTC CCC CTG GAC CCC TCG GCC TCC TCG TCC TCC CTG CCA CTG	3993
Glu Ser Val Pro Leu Asp Pro Ser Ala Ser Ser Ser Ser Leu Pro Leu	
1305 1310 1315	
CCC GAC AGA CAC TCA GGA CAC AAG GCC GAG AAC GGC CCC GGC CCT GGG	4041
Pro Asp Arg His Ser Gly His Lys Ala Glu Asn Gly Pro Gly Pro Gly	
1320 1325 1330	
GTG CTG GTC CTC CGC GCC AGC TTC GAC GAG AGA CAG CCT TAC GCC CAC	4089
Val Leu Val Leu Arg Ala Ser Phe Asp Glu Arg Gln Pro Tyr Ala His	
1335 1340 1345	
ATG AAC GGG GGC CGC AAG AAC GAG CGG GCC TTG CCG CTG CCC CAG TCT	4137
Met Asn Gly Gly Arg Lys Asn Glu Arg Ala Leu Pro Leu Pro Gln Ser	
1350 1355 1360	
TCG ACC TGC TGA TCCTTGGATC CTGAATCTGT GCAAACAGTA ACGTGTGCGC ACGCGC	4195
Ser Thr Cys	
1365	
AGCGGGGTGG GGGGGGAGAG AGAGTTTTAA CAATCCATTC ACAAGCCTCC TGTACCTCAG	4255
TGGATCTTCA GTTCTGCCCT TGCTGCCCCG GGGAGACAGC TTCTCTGCAG TAAAACACAT	4315
TTGGGATGTT CCTTTTTTCA ATATGCAAGC AGCTTTTTAT TCCCTGCCCA AACCCTTAAC	4375
TGACATGGGC CTTTAAGAAC CTTAATGACA ACACTTAATA GCAACAGAGC ACTTGAGAAC	4435
CAGTCTCCTC ACTCTGTCCC TGTCCTTCCC TGTTCTCCCT TTCTCTCTCC TCTCTGCTTC	4495
ATAACGGAAA AATAATTGCC ACAAGTCCAG CTGGGAAGCC CTTTTTATCA GTTTGAGGAA	4555
GTGGCTGTCC CTGTGGCCCC ATCCAACCAC TGTACACACC CGCCTGACAC CGTGGGTCAT	4615
TACAAAAAAA CACGTGGAGA TGGAAATTTT TACCTTTATC TTTCACCTTT CTAGGGACAT	4675
GAAATTTTACA AAGGGCCATC GTTCATCCAA GGCTGTTACC ATTTTAACGC TGCCTAATTT	4735
TGCCAAAATC CTGAACTTTC TCCCTCATCG GCCCGGCGCT GATTCCTCGT GTCCGGAGGC	4795
ATGGGTGAGC ATGGCAGCTG GTTGCTCCAT TTGAGAGACA CGCTGGCGAC ACACTCCGTC	4855
CATCCGACTG CCCCTGCTGT GCTGCTCAAG GCCACAGGCA CACAGGTCTC ATTGCTTCTG	4915
ACTAGATTAT TATTTGGGGG AACTGGACAC AATAGGTCTT TCTCTCAGTG AAGGTGGGGA	4975
GAAGCTGAAC CGGC	4989

We Claim:

1. A therapeutic composition for inhibiting the growth of breast cancer cells, comprising:
an immunogen derived from breast cancer cells treated with an IGF-1 receptor antisense oligonucleotide.
2. The composition of claim 1, wherein the immunogen comprises IGF-1 receptor antisense oligonucleotide-treated, inactivated breast cancer cells.
3. The composition of claim 2, wherein the inactivated breast cancer cells are irradiated.
4. The composition of claim 1, wherein said breast cancer cells are obtained from a patient to be treated with the therapeutic composition.
5. The composition of claim 1, wherein the immunogen is derived from a permanent breast tumor cell line.
6. The composition of claim 1, wherein the IGF-1 receptor antisense oligonucleotide comprises about 14 to about 25 sequential nucleotides.
7. The composition of claim 1, wherein the IGF-1 receptor antisense oligonucleotide has a sequence complementary to the nucleotide sequence of codons of the human IGF-1R precursor signal sequence, complementary to the nucleotide sequence at or near an initiation site, or complementary to sequences at or near a site for ribosome complex assembly.
8. The composition of claim 1, wherein the IGF-1 receptor antisense oligonucleotide includes the following sequence:

5' TCC TCC GGA GCC AGA CTT 3' [SEQ ID NO:1] or
5' ACT CGT CGG CCA GAG CGA GAG 3' [SEQ ID NO:2].


9. The composition of claim 1, wherein the IGF-1R antisense oligonucleotide comprises a synthetic base or a modified backbone.
10. An anti-breast tumor vaccine comprising:
a tumor immunogen derived from a breast cancer cell treated with an IGF-1 receptor antisense oligonucleotide in a pharmaceutically acceptable carrier.
11. An IGF-1 receptor antisense oligonucleotide having the sequence: 5' ACT CGT CGG CCA GAG CGA GAG 3' [SEQ ID NO:2].
12. A method of inhibiting the growth of breast cancer cells in a patient, the method comprising:
administering to a patient an immunogen derived from breast cancer cells treated with an IGF-1 receptor antisense oligonucleotide.
13. The method of claim 12, wherein said administering is subsequent to or concurrent with tumor reduction therapy.
14. The method of claim 13, wherein said administering is subsequent to surgical debulking of tumors.
15. The method of claim 12, wherein the IGF-1 receptor antisense oligonucleotide comprises about 14 to about 25 sequential nucleotides.
16. The method of claim 12, wherein the IGF-1 receptor antisense oligonucleotide has a sequence complementary to the nucleotide sequence of codons of the human IGF-1R precursor signal sequence, complementary to the nucleotide sequence at or near an initiation site, or complementary to sequences at or near a site for ribosome complex assembly.
17. The method of claim 12, wherein the IGF-1 receptor antisense oligonucleotide includes the following sequence:

5' TCC TCC GGA GCC AGA CTT 3' [SEQ ID NO:1] or
5' ACT CGT CGG CCA GAG CGA GAG 3' [SEQ ID NO:2].

18. A method of preparing an immunogen to inhibit growth of breast cancer cells, the method comprising:
- treating breast cancer cells with an IGF-1 receptor antisense oligonucleotide;
 - and
 - inactivating said breast cancer cells.


1/14

FIG. 1




2/14

FIG. 2




3/14

FIG. 3




4/14

FIG. 4



5/14

FIG. 5



6/14

Fig. 6A

TTTTTTTTTT TTTTGAGAAA GCGAATTTC TCCCAAATAA AAGGA ATG AAG TCT GGC	57
Met Lys Ser Gly	
1	
TCC GGA GGA GGG TCC CCG ACC TCG CTG TGG GGG CTC CTG TTT CTC TCC	105
Ser Gly Gly Gly Ser Pro Thr Ser Leu Trp Gly Leu Leu Phe Leu Ser	
5 10 15 20	
GCC GCG CTC TCG CTC TGG CCG ACG AGT GGA GAA ATC TGC GGG CCA GGC	153
Ala Ala Leu Ser Leu Trp Pro Thr Ser Gly Glu Ile Cys Gly Pro Gly	
25 30 35	
ATC GAC ATC CGC AAC GAC TAT CAG CAG CTG AAG CGC CTG GAG AAC TGC	201
Ile Asp Ile Arg Asn Asp Tyr Gln Gln Leu Lys Arg Leu Glu Asn Cys	
40 45 50	
ACG GTG ATC GAG GGC TAC CTC CAC ATC CTG CTC ATC TCC AAG GCC GAG	249
Thr Val Ile Glu Gly Tyr Leu His Ile Leu Leu Ile Ser Lys Ala Glu	
55 60 65	
GAC TAC CGC AGC TAC CGC TTC CCC AAG CTC ACG GTC ATT ACC GAG TAC	297
Asp Tyr Arg Ser Tyr Arg Phe Pro Lys Leu Thr Val Ile Thr Glu Tyr	
70 75 80	
TTG CTG CTG TTC CGA GTG GCT GGC CTC GAG AGC CTC GGA GAC CTC TTC	345
Leu Leu Leu Phe Arg Val Ala Gly Leu Glu Ser Leu Gly Asp Leu Phe	
85 90 95 100	
CCC AAC CTC ACG GTC ATC CGC GGC TGG AAA CTC TTC TAC AAC TAC GCC	393
Pro Asn Leu Thr Val Ile Arg Gly Trp Lys Leu Phe Tyr Asn Tyr Ala	
105 110 115	
CTG GTC ATC TTC GAG ATG ACC AAT CTC AAG GAT ATT GGG CTT TAC AAC	441
Leu Val Ile Phe Glu Met Thr Asn Leu Lys Asp Ile Gly Leu Tyr Asn	
120 125 130	
CTG AGG AAC ATT ACT CGG GGG GCC ATC AGG ATT GAG AAA AAT GCT GAC	489
Leu Arg Asn Ile Thr Arg Gly Ala Ile Arg Ile Glu Lys Asn Ala Asp	
135 140 145	
CTC TGT TAC CTC TCC ACT GTG GAC TGG TCC CTG ATC CTG GAT GCG GTG	537
Leu Cys Tyr Leu Ser Thr Val Asp Trp Ser Leu Ile Leu Asp Ala Val	
150 155 160	

7/14

Fig. 6B

TCC AAT AAC TAC ATT GTG GGG AAT AAG CCC CCA AAG GAA TGT GGG GAC Ser Asn Asn Tyr Ile Val Gly Asn Lys Pro Pro Lys Glu Cys Gly Asp 165 170 175 180	585
CTG TGT CCA GGG ACC ATG GAG GAG AAG CCG ATG TGT GAG AAG ACC ACC Leu Cys Pro Gly Thr Met Glu Glu Lys Pro Met Cys Glu Lys Thr Thr 185 190 195	633
ATC AAC AAT GAG TAC AAC TAC CGC TGC TGG ACC ACA AAC CGC TGC CAG Ile Asn Asn Glu Tyr Asn Tyr Arg Cys Trp Thr Thr Asn Arg Cys Gln 200 205 210	681
AAA ATG TGC CCA AGC ACG TGT GGG AAG CGG GCG TGC ACC GAG AAC AAT Lys Met Cys Pro Ser Thr Cys Gly Lys Arg Ala Cys Thr Glu Asn Asn 215 220 225	729
GAG TGC TGC CAC CCC GAG TGC CTG GGC AGC TGC AGC GCG CCT GAC AAC Glu Cys Cys His Pro Glu Cys Leu Gly Ser Cys Ser Ala Pro Asp Asn 230 235 240	777
GAC ACG GCC TGT GTA GCT TGC CGC CAC TAC TAC TAT GCC GGT GTC TGT Asp Thr Ala Cys Val Ala Cys Arg His Tyr Tyr Tyr Ala Gly Val Cys 245 250 255 260	825
GTG CCT GCC TGC CCG CCC AAC ACC TAC AGG TTT GAG GGC TGG CGC TGT Val Pro Ala Cys Pro Pro Asn Thr Tyr Arg Phe Glu Gly Trp Arg Cys 265 270 275	873
GTG GAC CGT GAC TTC TGC GCC AAC ATC CTC AGC GCC GAG AGC AGC GAC Val Asp Arg Asp Phe Cys Ala Asn Ile Leu Ser Ala Glu Ser Ser Asp 280 285 290	921
TCC GAG GGG TTT GTG ATC CAC GAC GGC GAG TGC ATG CAG GAG TGC CCC Ser Glu Gly Phe Val Ile His Asp Gly Glu Cys Met Gln Glu Cys Pro 295 300 305	969
TCG GGC TTC ATC CGC AAC GGC AGC CAG AGC ATG TAC TGC ATC CCT TGT Ser Gly Phe Ile Arg Asn Gly Ser Gln Ser Met Tyr Cys Ile Pro Cys 310 315 320	1017
GAA GGT CCT TGC CCG AAG GTC TGT GAG GAA GAA AAG AAA ACA AAG ACC Glu Gly Pro Cys Pro Lys Val Cys Glu Glu Glu Lys Lys Thr Lys Thr 325 330 335 340	1065

8/14

Fig. 6C

ATT GAT TCT GTT ACT TCT GCT CAG ATG CTC CAA GGA TGC ACC ATC TTC	1113
Ile Asp Ser Val Thr Ser Ala Gln Met Leu Gln Gly Cys Thr Ile Phe	
345 350 355	
AAG GGC AAT TTG CTC ATT AAC ATC CGA CGG GGG AAT AAC ATT GCT TCA	1161
Lys Gly Asn Leu Leu Ile Asn Ile Arg Arg Gly Asn Asn Ile Ala Ser	
360 365 370	
GAG CTG GAG AAC TTC ATG GGG CTC ATC GAG GTG GTG ACG GGC TAC GTG	1209
Glu Leu Glu Asn Phe Met Gly Leu Ile Glu Val Val Thr Gly Tyr Val	
375 380 385	
AAG ATC CGC CAT TCT CAT GCC TTG GTC TCC TTG TCC TTC CTA AAA AAC	1257
Lys Ile Arg His Ser His Ala Leu Val Ser Leu Ser Phe Leu Lys Asn	
390 395 400	
CTT CGC CTC ATC CTA GGA GAG GAG CAG CTA GAA GGG AAT TAC TCC TTC	1305
Leu Arg Leu Ile Leu Gly Glu Glu Gln Leu Glu Gly Asn Tyr Ser Phe	
405 410 415 420	
TAC GTC CTC GAC AAC CAG AAC TTG CAG CAA CTG TGG GAC TGG GAC CAC	1353
Tyr Val Leu Asp Asn Gln Asn Leu Gln Gln Leu Trp Asp Trp Asp His	
425 430 435	
CGC AAC CTG ACC ATC AAA GCA GGG AAA ATG TAC TTT GCT TTC AAT CCC	1401
Arg Asn Leu Thr Ile Lys Ala Gly Lys Met Tyr Phe Ala Phe Asn Pro	
440 445 450	
AAA TTA TGT GTT TCC GAA ATT TAC CGC ATG GAG GAA GTG ACG GGG ACT	1449
Lys Leu Cys Val Ser Glu Ile Tyr Arg Met Glu Glu Val Thr Gly Thr	
455 460 465	
AAA GGG CGC CAA AGC AAA GGG GAC ATA AAC ACC AGG AAC AAC GGG GAG	1497
Lys Gly Arg Gln Ser Lys Gly Asp Ile Asn Thr Arg Asn Asn Gly Glu	
470 475 480	
AGA GCC TCC TGT GAA AGT GAC GTC CTG CAT TTC ACC TCC ACC ACC ACG	1545
Arg Ala Ser Cys Glu Ser Asp Val Leu His Phe Thr Ser Thr Thr Thr	
485 490 495 500	
TCG AAG AAT CGC ATC ATC ATA ACC TGG CAC CGG TAC CGG CCC CCT GAC	1593
Ser Lys Asn Arg Ile Ile Ile Thr Trp His Arg Tyr Arg Pro Pro Asp	
505 510 515	

9/14

Fig. 6D

TAC	AGG	GAT	CTC	ATC	AGC	TTC	ACC	GTT	TAC	TAC	AAG	GAA	GCA	CCC	TTT	1641
Tyr	Arg	Asp	Leu	Ile	Ser	Phe	Thr	Val	Tyr	Tyr	Lys	Glu	Ala	Pro	Phe	
			520					525					530			
AAG	AAT	GTC	ACA	GAG	TAT	GAT	GGG	CAG	GAT	GCC	TGC	GGC	TCC	AAC	AGC	1689
Lys	Asn	Val	Thr	Glu	Tyr	Asp	Gly	Gln	Asp	Ala	Cys	Gly	Ser	Asn	Ser	
		535					540					545				
TGG	AAC	ATG	GTG	GAC	GTG	GAC	CTC	CCG	CCC	AAC	AAG	GAC	GTG	GAG	CCC	1737
Trp	Asn	Met	Val	Asp	Val	Asp	Leu	Pro	Pro	Asn	Lys	Asp	Val	Glu	Pro	
		550					555					560				
GGC	ATC	TTA	CTA	CAT	GGG	CTG	AAG	CCC	TGG	ACT	CAG	TAC	GCC	GTT	TAC	1785
Gly	Ile	Leu	Leu	His	Gly	Leu	Lys	Pro	Trp	Thr	Gln	Tyr	Ala	Val	Tyr	
565					570					575					580	
GTC	AAG	GCT	GTG	ACC	CTC	ACC	ATG	GTG	GAG	AAC	GAC	CAT	ATC	CGT	GGG	1833
Val	Lys	Ala	Val	Thr	Leu	Thr	Met	Val	Glu	Asn	Asp	His	Ile	Arg	Gly	
				585					590					595		
GCC	AAG	AGT	GAG	ATC	TTG	TAC	ATT	CGC	ACC	AAT	GCT	TCA	GTT	CCT	TCC	1881
Ala	Lys	Ser	Glu	Ile	Leu	Tyr	Ile	Arg	Thr	Asn	Ala	Ser	Val	Pro	Ser	
			600					605					610			
ATT	CCC	TTG	GAC	GTT	CTT	TCA	GCA	TCG	AAC	TCC	TCT	TCT	CAG	TTA	ATC	1929
Ile	Pro	Leu	Asp	Val	Leu	Ser	Ala	Ser	Asn	Ser	Ser	Ser	Gln	Leu	Ile	
		615					620						625			
GTG	AAG	TGG	AAC	CCT	CCC	TCT	CTG	CCC	AAC	GGC	AAC	CTG	AGT	TAC	TAC	1977
Val	Lys	Trp	Asn	Pro	Pro	Ser	Leu	Pro	Asn	Gly	Asn	Leu	Ser	Tyr	Tyr	
		630					635					640				
ATT	GTG	CGC	TGG	CAG	CGG	CAG	CCT	CAG	GAC	GGC	TAC	CTT	TAC	CGG	CAC	2025
Ile	Val	Arg	Trp	Gln	Arg	Gln	Pro	Gln	Asp	Gly	Tyr	Leu	Tyr	Arg	His	
645					650					655					660	
AAT	TAC	TGC	TCC	AAA	GAC	AAA	ATC	CCC	ATC	AGG	AAG	TAT	GCC	GAC	GGC	2073
Asn	Tyr	Cys	Ser	Lys	Asp	Lys	Ile	Pro	Ile	Arg	Lys	Tyr	Ala	Asp	Gly	
				665					670					675		
ACC	ATC	GAC	ATT	GAG	GAG	GTC	ACA	GAG	AAC	CCC	AAG	ACT	GAG	GTG	TGT	2121
Thr	Ile	Asp	Ile	Glu	Glu	Val	Thr	Glu	Asn	Pro	Lys	Thr	Glu	Val	Cys	
			680					685						690		

10/14

Fig. 6E

GGT	GGG	GAG	AAA	GGG	CCT	TGC	TGC	GCC	TGC	CCC	AAA	ACT	GAA	GCC	GAG	2169
Gly	Gly	Glu	Lys	Gly	Pro	Cys	Cys	Ala	Cys	Pro	Lys	Thr	Glu	Ala	Glu	
		695					700					705				
AAG	CAG	GCC	GAG	AAG	GAG	GAG	GCT	GAA	TAC	CGC	AAA	GTC	TTT	GAG	AAT	2217
Lys	Gln	Ala	Glu	Lys	Glu	Glu	Ala	Glu	Tyr	Arg	Lys	Val	Phe	Glu	Asn	
		710				715					720					
TTC	CTG	CAC	AAC	TCC	ATC	TTC	GTG	CCC	AGA	CCT	GAA	AGG	AAG	CGG	AGA	2265
Phe	Leu	His	Asn	Ser	Ile	Phe	Val	Pro	Arg	Pro	Glu	Arg	Lys	Arg	Arg	
725					730					735					740	
GAT	GTC	ATG	CAA	GTG	GCC	AAC	ACC	ACC	ATG	TCC	AGC	CGA	AGC	AGG	AAC	2313
Asp	Val	Met	Gln	Val	Ala	Asn	Thr	Thr	Met	Ser	Ser	Arg	Ser	Arg	Asn	
			745						750					755		
ACC	ACG	GCC	GCA	GAC	ACC	TAC	AAC	ATC	ACC	GAC	CCG	GAA	GAG	CTG	GAG	2361
Thr	Thr	Ala	Ala	Asp	Thr	Tyr	Asn	Ile	Thr	Asp	Pro	Glu	Glu	Leu	Glu	
		760						765					770			
ACA	GAG	TAC	CCT	TTC	TTT	GAG	AGC	AGA	GTG	GAT	AAC	ACG	GAG	AGA	ACT	2409
Thr	Glu	Tyr	Pro	Phe	Phe	Glu	Ser	Arg	Val	Asp	Asn	Thr	Glu	Arg	Thr	
		775					780					785				
GTC	ATT	TCT	AAC	CTT	CGG	CCT	TTC	ACA	TTG	TAC	CGC	ATC	GAT	ATC	CAC	2457
Val	Ile	Ser	Asn	Leu	Arg	Pro	Phe	Thr	Leu	Tyr	Arg	Ile	Asp	Ile	His	
	790					795					800					
AGC	TGC	AAC	CAC	GAG	GCT	GAG	AAG	CTG	GGC	TGC	AGC	GCC	TCC	AAC	TTC	2505
Ser	Cys	Asn	His	Glu	Ala	Glu	Lys	Leu	Gly	Cys	Ser	Ala	Ser	Asn	Phe	
805				810					815						820	
GTC	TTT	GCA	AGG	ACT	ATG	CCC	GCA	GAA	GGA	GCA	GAT	GAC	ATT	CCT	GGG	2553
Val	Phe	Ala	Arg	Thr	Met	Pro	Ala	Glu	Gly	Ala	Asp	Asp	Ile	Pro	Gly	
			825					830						835		
CCA	GTG	ACC	TGG	GAG	CCA	AGG	CCT	GAA	AAC	TCC	ATC	TTT	TTA	AAG	TGG	2601
Pro	Val	Thr	Trp	Glu	Pro	Arg	Pro	Glu	Asn	Ser	Ile	Phe	Leu	Lys	Trp	
		840						845					850			
CCG	GAA	CCT	GAG	AAT	CCC	AAT	GGA	TTG	ATT	CTA	ATG	TAT	GAA	ATA	AAA	2649
Pro	Glu	Pro	Glu	Asn	Pro	Asn	Gly	Leu	Ile	Leu	Met	Tyr	Glu	Ile	Lys	
		855					860					865				

11/14

Fig. 6F

TAC GGA TCA CAA GTT GAG GAT CAG CGA GAA TGT GTG TCC AGA CAG GAA	2697
Tyr Gly Ser Gln Val Glu Asp Gln Arg Glu Cys Val Ser Arg Gln Glu	
870 875 880	
TAC AGG AAG TAT GGA GGG GCC AAG CTA AAC CGG CTA AAC CCG GGG AAC	2745
Tyr Arg Lys Tyr Gly Gly Ala Lys Leu Asn Arg Leu Asn Pro Gly Asn	
885 890 895 900	
TAC ACA GCC CGG ATT CAG GCC ACA TCT CTC TCT GGG AAT GGG TCG TGG	2793
Tyr Thr Ala Arg Ile Gln Ala Thr Ser Leu Ser Gly Asn Gly Ser Trp	
905 910 915	
ACA GAT CCT GTG TTC TTC TAT GTC CAG GCC AAA ACA GGA TAT GAA AAC	2841
Thr Asp Pro Val Phe Phe Tyr Val Gln Ala Lys Thr Gly Tyr Glu Asn	
920 925 930	
TTC ATC CAT CTG ATC ATC GCT CTG CCC GTC GCT GTC CTG TTG ATC GTG	2889
Phe Ile His Leu Ile Ile Ala Leu Pro Val Ala Val Leu Leu Ile Val	
935 940 945	
GGA GGG TTG GTG ATT ATG CTG TAC GTC TTC CAT AGA AAG AGA AAT AAC	2937
Gly Gly Leu Val Ile Met Leu Tyr Val Phe His Arg Lys Arg Asn Asn	
950 955 960	
AGC AGG CTG GGG AAT GGA GTG CTG TAT GCC TCT GTG AAC CCG GAG TAC	2985
Ser Arg Leu Gly Asn Gly Val Leu Tyr Ala Ser Val Asn Pro Glu Tyr	
965 970 975 980	
TTC AGC GCT GCT GAT GTG TAC GTT CCT GAT GAG TGG GAG GTG GCT CGG	3033
Phe Ser Ala Ala Asp Val Tyr Val Pro Asp Glu Trp Glu Val Ala Arg	
985 990 995	
GAG AAG ATC ACC ATG AGC CGG GAA CTT GGG CAG GGG TCG TTT GGG ATG	3081
Glu Lys Ile Thr Met Ser Arg Glu Leu Gly Gln Gly Ser Phe Gly Met	
1000 1005 1010	
GTC TAT GAA GGA GTT GCC AAG GGT GTG GTG AAA GAT GAA CCT GAA ACC	3129
Val Tyr Glu Gly Val Ala Lys Gly Val Val Lys Asp Glu Pro Glu Thr	
1015 1020 1025	
AGA GTG GCC ATT AAA ACA GTG AAC GAG GCC GCA AGC ATG CGT GAG AGG	3177
Arg Val Ala Ile Lys Thr Val Asn Glu Ala Ala Ser Met Arg Glu Arg	
1030 1035 1040	

12/14

Fig. 6G

ATT GAG TTT CTC AAC GAA GCT TCT GTG ATG AAG GAG TTC AAT TGT CAC	3225
Ile Glu Phe Leu Asn Glu Ala Ser Val Met Lys Glu Phe Asn Cys His	
1045 1050 1055 1060	
CAT GTG GTG CGA TTG CTG GGT GTG GTG TCC CAA GGC CAG CCA ACA CTG	3273
His Val Val Arg Leu Leu Gly Val Val Ser Gln Gly Gln Pro Thr Leu	
1065 1070 1075	
GTC ATC ATG GAA CTG ATG ACA CGG GGC GAT CTC AAA AGT TAT CTC CGG	3321
Val Ile Met Glu Leu Met Thr Arg Gly Asp Leu Lys Ser Tyr Leu Arg	
1080 1085 1090	
TCT CTG AGG CCA GAA ATG GAG AAT AAT CCA GTC CTA GCA CCT CCA AGC	3369
Ser Leu Arg Pro Glu Met Glu Asn Asn Pro Val Leu Ala Pro Pro Ser	
1095 1100 1105	
CTG AGC AAG ATG ATT CAG ATG GCC GGA GAG ATT GCA GAC GGC ATG GCA	3417
Leu Ser Lys Met Ile Gln Met Ala Gly Glu Ile Ala Asp Gly Met Ala	
1110 1115 1120	
TAC CTC AAC GCC AAT AAG TTC GTC CAC AGA GAC CTT GCT GCC CGG AAT	3465
Tyr Leu Asn Ala Asn Lys Phe Val His Arg Asp Leu Ala Ala Arg Asn	
1125 1130 1135 1140	
TGC ATG GTA GCC GAA GAT TTC ACA GTC AAA ATC GGA GAT TTT GGT ATG	3513
Cys Met Val Ala Glu Asp Phe Thr Val Lys Ile Gly Asp Phe Gly Met	
1145 1150 1155	
ACG CGA GAT ATC TAT GAG ACA GAC TAT TAC CGG AAA GGA GGC AAA GGG	3561
Thr Arg Asp Ile Tyr Glu Thr Asp Tyr Tyr Arg Lys Gly Gly Lys Gly	
1160 1165 1170	
CTG CTG CCC GTG CGC TGG ATG TCT CCT GAG TCC CTC AAG GAT GGA GTC	3609
Leu Leu Pro Val Arg Trp Met Ser Pro Glu Ser Leu Lys Asp Gly Val	
1175 1180 1185	
TTC ACC ACT TAC TCG GAC GTC TGG TCC TTC GGG GTC GTC CTC TGG GAG	3657
Phe Thr Thr Tyr Ser Asp Val Trp Ser Phe Gly Val Val Leu Trp Glu	
1190 1195 1200	
ATC GCC ACA CTG GCC GAG CAG CCC TAC CAG GGC TTG TCC AAC GAG CAA	3705
Ile Ala Thr Leu Ala Glu Gln Pro Tyr Gln Gly Leu Ser Asn Glu Gln	
1205 1210 1215 1220	

13/14

Fig. 6H

GTC CTT CGC TTC GTC ATG GAG GGC GGC CTT CTG GAC AAG CCA GAC AAC	3753
Val Leu Arg Phe Val Met Glu Gly Gly Leu Leu Asp Lys Pro Asp Asn	
1225 1230 1235	
TGT CCT GAC ATG CTG TTT GAA CTG ATG CGC ATG TGC TGG CAG TAT AAC	3801
Cys Pro Asp Met Leu Phe Glu Leu Met Arg Met Cys Trp Gln Tyr Asn	
1240 1245 1250	
CCC AAG ATG AGG CCT TCC TTC CTG GAG ATC ATC AGC AGC ATC AAA GAG	3849
Pro Lys Met Arg Pro Ser Phe Leu Glu Ile Ile Ser Ser Ile Lys Glu	
1255 1260 1265	
GAG ATG GAG CCT GGC TTC CGG GAG GTC TCC TTC TAC TAC AGC GAG GAG	3897
Glu Met Glu Pro Gly Phe Arg Glu Val Ser Phe Tyr Tyr Ser Glu Glu	
1270 1275 1280	
AAC AAG CTG CCC GAG CCG GAG GAG CTG GAC CTG GAG CCA GAG AAC ATG	3945
Asn Lys Leu Pro Glu Pro Glu Glu Leu Asp Leu Glu Pro Glu Asn Met	
1285 1290 1295 1300	
GAG AGC GTC CCC CTG GAC CCC TCG GCC TCC TCG TCC TCC CTG CCA CTG	3993
Glu Ser Val Pro Leu Asp Pro Ser Ala Ser Ser Ser Ser Leu Pro Leu	
1305 1310 1315	
CCC GAC AGA CAC TCA GGA CAC AAG GCC GAG AAC GGC CCC GGC CCT GGG	4041
Pro Asp Arg His Ser Gly His Lys Ala Glu Asn Gly Pro Gly Pro Gly	
1320 1325 1330	
GTG CTG GTC CTC CGC GCC AGC TTC GAC GAG AGA CAG CCT TAC GCC CAC	4089
Val Leu Val Leu Arg Ala Ser Phe Asp Glu Arg Gln Pro Tyr Ala His	
1335 1340 1345	
ATG AAC GGG GGC CGC AAG AAC GAG CGG GCC TTG CCG CTG CCC CAG TCT	4137
Met Asn Gly Gly Arg Lys Asn Glu Arg Ala Leu Pro Leu Pro Gln Ser	
1350 1355 1360	
TCG ACC TGC TGA TCCTTGGATC CTGAATCTGT GCAAACAGTA ACGTGTGCGC ACGCGC	4195
Ser Thr Cys	
1365	
AGCGGGGTGG GGGGGGAGAG AGAGTTTTAA CAATCCATTC ACAAGCCTCC TGTACCTCAG	4255
TGGATCTTCA GTTCTGCCCT TGCTGCCCGC GGGAGACAGC TTCTCTGCAG TAAACACAT	4315
TTGGGATGTT CCTTTTTTCA ATATGCAAGC AGCTTTTAT TCCCTGCCCA AACCCTTAAC	4375
TGACATGGGC CTTTAAGAAC CTTAATGACA AACTTAATA GCAACAGAGC ACTTGAGAAC	4435
CAGTCTCCTC ACTCTGTCCC TGTCCTTCCC TGTTCTCCCT TTCTCTCTCC TCTCTGCTTC	4495

14/14

Fig. 6I

ATAACGGAAA	AATAATTGCC	ACAAGTCCAG	CTGGGAAGCC	CTTTTTATCA	GTTTGAGGAA	4555
GTGGCTGTCC	CTGTGGCCCC	ATCCAACCAC	TGTACACACC	CGCCTGACAC	CGTGGGTCAT	4615
TACAAAAAAA	CACGTGGAGA	TGGAAATTTT	TACCTTTATC	TTTCACCTTT	CTAGGGACAT	4675
GAAATTTACA	AAGGGCCATC	GTTTCATCCAA	GGCTGTTACC	ATTTTAAACGC	TGCCTAATTT	4735
TGCCAAAATC	CTGAACTTTC	TCCCTCATCG	GCCCGGCGCT	GATTCCTCGT	GTCCGGAGGC	4795
ATGGGTGAGC	ATGGCAGCTG	GTTGCTCCAT	TTGAGAGACA	CGCTGGCGAC	ACACTCCGTC	4855
CATCCGACTG	CCCCTGCTGT	GCTGCTCAGG	GCCACAGGCA	CACAGGTCTC	ATTGCTTCTG	4915
ACTAGATTAT	TATTGGGGG	AACTGGACAC	AATAGGTCTT	TCTCTCAGTG	AAGGTGGGGA	4975
GAAGCTGAAC	CGGC					4989

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/20815

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/11 A61K45/05

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C07H C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WALLENFRIEDMAN M A ET AL: "IGF - 1 R antisense and nonsense oligonucleotide therapy for 9L glioblastoma results in an immune response against an unrelated syngeneic tumor in Fischer 344 rats." 26TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, WASHINGTON, D.C., USA, NOVEMBER 16-21, 1996. SOCIETY FOR NEUROSCIENCE ABSTRACTS 22 (1-3). 1996. 948. ISSN: 0190-5295, XP002055143 see the whole document</p> <p style="text-align: center;">--- -/--</p>	1-18

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 March 1998

Date of mailing of the international search report

20. 03. 98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mennessier, T

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/20815

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WALLENFRIEDMAN M A ET AL: "Effects of IGF-1R antisense and nonsense oligonucleotide administration on 9L glioblastoma and MAT B3 breast cancer tumor growth in Fischer 344 rats." 87TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, WASHINGTON, D.C., USA, APRIL 20-24, 1996. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 37 (0). 1996. 354. ISSN: 0197-016X, XP002055144 see the whole document</p>	1-18
A	<p>--- BASERGA R: "Controlling IGF-receptor function: a possible strategy for tumor therapy" TRENDS IN BIOTECHNOLOGY, vol. 14, no. 5, May 1996, page 150-152 XP004035784 see the whole document</p>	1-18
A	<p>--- WO 94 22486 A (UNIV JEFFERSON ;BASERGA RENATO (US); SELL CHRISTIAN (US); RUBIN RA) 13 October 1994 see page 33; figure 7A</p>	8,11,17
P,X	<p>--- WALLENFRIEDMAN M ET AL: "Peripheral vaccine for breast cancer: Insulin-like growth factor receptor (IGF - 1R) antisense oligonucleotide (AON) modified tumor cells protect against peripheral disease and brain metastases." EIGHTY-EIGHTH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, SAN DIEGO, CALIFORNIA, USA, APRIL 12-16, 1997. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 38 (0). 1997. 617. ISSN: 0197-016X, XP002055145 see the whole document</p> <p>-----</p>	1-18

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/20815

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 12 - 17
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 12-17 are directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/20815

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9422486 A	13-10-94	CA 2158347 A	13-10-94
		EP 0750516 A	02-01-97
		JP 8508405 T	10-09-96
		US 5643788 A	01-07-97
